Tocilizumab treatment and outcomes in severe COVID-19 patients: Retrospective study from a tertiary care institute in western India
Background: Coronavirus disease 2019 (COVID-19) is a pandemic caused by a novel beta coronavirus severe acute respiratory syndrome coronavirus (SARS-CoV-2). The symptoms range from mild to severe in nature. The severity of respiratory symptoms is due to the cytokine storm. The tocilizumab, interleu...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KIMS Foundation and Research Center
2020-12-01
|
| Series: | Journal of Medical and Scientific Research |
| Subjects: | |
| Online Access: | http://jmsronline.com/article.aspx?ID=Tocilizumab-treatment-and-outcomes-in-severe-COVID-19-patients |